No changes of cardiometabolic and body composition parameters after 6-month add-on treatment with sarcosine in patients with schizophrenia

Psychiatry Research
Dominik StrzeleckiAdam Wysokiński

Abstract

This study was undertaken with the purpose to determine if there are changes in metabolic parameters during 6-month add-on treatment with sarcosine in patients with schizophrenia. This was a randomized double blind, placebo-controlled and parallel group study. Eligible participants were randomly assigned to receive 2g of sarcosine (n=30) or placebo (n=29). Sarcosine was administered as supplementation to the ongoing antipsychotic treatment. Augmentation with sarcosine had no effect on any of the analyzed cardiometabolic parameters. Also, augmentation with sarcosine had no effect on any of the analyzed body composition parameters. This is the first randomized placebo-controlled study to examine the metabolic safety of sarcosine in patients with schizophrenia. Clinically, this observation is of high importance considering how prevalent are metabolic abnormalities in patients with schizophrenia.

References

Jan 11, 2000·Journal of Psychiatric Research·J W OlneyN B Farber
Mar 17, 2000·Brain Research. Brain Research Reviews·A CarlssonM L Carlsson
Jan 16, 2002·JAMA : the Journal of the American Medical Association·Earl S FordWilliam H Dietz
Jan 21, 2004·Biological Psychiatry·Uriel Heresco-LevyDaniel C Javitt
May 18, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Dirk Vordermark
Sep 13, 2005·Biological Psychiatry·Guochuan E TsaiMian-Yoon Chong
May 10, 2006·Diabetic Medicine : a Journal of the British Diabetic Association·K G M M AlbertiJ Shaw
Oct 24, 2006·Pharmacoepidemiology and Drug Safety·Pascal AuquierCatriona Holmes
May 16, 2008·Epidemiologic Reviews·John McGrathJoy Welham
Jul 22, 2009·Neuropharmacology·Hai Xia ZhangLiu Lin Thio
Sep 16, 2009·PloS One·Thomas L KellySteven B Heymsfield
Nov 6, 2009·The International Journal of Neuropsychopharmacology·Hsien-Yuan LaneGuochuan E Tsai
Feb 3, 2012·Current Opinion in Psychiatry·Joshua Kantrowitz, Daniel C Javitt
Nov 23, 2012·Schizophrenia Bulletin·Erika JääskeläinenJouko Miettunen
Feb 1, 2011·Therapeutic Advances in Psychopharmacology·James M Stone
Feb 4, 2014·Schizophrenia Research·Christopher K CainDonald C Goff
Apr 17, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D Bugarski-KirolaT Blättler
Apr 26, 2014·PloS One·Maarten BakMarjan Drukker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Autism

Autism spectrum disorder is associated with challenges with social skills, repetitive behaviors, and often accompanied by sensory sensitivities and medical issues. Here is the latest research on autism.